TY - JOUR
T1 - Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia
AU - St. Sauver, Jennifer L.
AU - Jacobson, Debra J.
AU - Mcgree, Michaela E.
AU - Lieber, Michael M.
AU - Jacobsen, Steven J.
N1 - Funding Information:
This project was supported by research grants from the Public Health Service, National Institutes of Health (DK58859, AR30582, and RR000585). The authors thank the Olmsted County Study personnel for their help with the study and Sondra Buehler for her assistance in preparing this manuscript. Conflict of interest: none declared.
PY - 2006/10
Y1 - 2006/10
N2 - In 1990-2002, the authors conducted a population-based cohort study of 2,447 Caucasian men in Olmsted County, Minnesota, to determine whether daily users of nonsteroidal antiinflammatory drugs (NSAIDs) were at lower risk than nondaily NSAID users of developing benign prostatic hyperplasia. Participants completed validated questionnaires during a home visit, including information about daily NSAID use. A random subset of 634 men also participated in a clinical evaluation including transrectal ultrasonography and assessment of serum prostate-specific antigen levels. Examinations and questionnaires were repeated biennially through 2002. Benign prostatic hyperplasia measures included development of moderate/severe urinary symptoms (American Urological Association Symptom Index score >7), low maximum urinary flow rate (<12 ml/second), prostate volume >30 ml, or prostate-specific antigen level >1.4 ng/ml. After adjustment for age, daily NSAID use was inversely associated with onset of moderate/severe urinary symptoms (hazard ratio (HR) = 0.73, 95% confidence interval (CI): 0.64, 0.82), low maximum flow rate (HR = 0.51, 95% CI: 0.43, 0.61), increased prostate volume (HR = 0.53, 95% CI: 0.41, 0.68), and elevated prostate-specific antigen level (HR = 0.52, 95% CI: 0.40, 0.68). In age-specific analyses, inverse associations between NSAID use and urinary measures tended to be stronger in the oldest age groups, although this interaction was statistically significant for only obstructive symptoms and treatment. Results suggest that NSAID use may prevent or delay development of benign prostatic hyperplasia.
AB - In 1990-2002, the authors conducted a population-based cohort study of 2,447 Caucasian men in Olmsted County, Minnesota, to determine whether daily users of nonsteroidal antiinflammatory drugs (NSAIDs) were at lower risk than nondaily NSAID users of developing benign prostatic hyperplasia. Participants completed validated questionnaires during a home visit, including information about daily NSAID use. A random subset of 634 men also participated in a clinical evaluation including transrectal ultrasonography and assessment of serum prostate-specific antigen levels. Examinations and questionnaires were repeated biennially through 2002. Benign prostatic hyperplasia measures included development of moderate/severe urinary symptoms (American Urological Association Symptom Index score >7), low maximum urinary flow rate (<12 ml/second), prostate volume >30 ml, or prostate-specific antigen level >1.4 ng/ml. After adjustment for age, daily NSAID use was inversely associated with onset of moderate/severe urinary symptoms (hazard ratio (HR) = 0.73, 95% confidence interval (CI): 0.64, 0.82), low maximum flow rate (HR = 0.51, 95% CI: 0.43, 0.61), increased prostate volume (HR = 0.53, 95% CI: 0.41, 0.68), and elevated prostate-specific antigen level (HR = 0.52, 95% CI: 0.40, 0.68). In age-specific analyses, inverse associations between NSAID use and urinary measures tended to be stronger in the oldest age groups, although this interaction was statistically significant for only obstructive symptoms and treatment. Results suggest that NSAID use may prevent or delay development of benign prostatic hyperplasia.
KW - Anti-inflammatory agents
KW - Cohort studies
KW - Data collection
KW - Men
KW - Non-steroidal
KW - Prostate-specific antigen
KW - Prostatic hyperplasia
KW - Questionnaires
UR - http://www.scopus.com/inward/record.url?scp=33749460341&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33749460341&partnerID=8YFLogxK
U2 - 10.1093/aje/kwj258
DO - 10.1093/aje/kwj258
M3 - Article
C2 - 16905643
AN - SCOPUS:33749460341
SN - 0002-9262
VL - 164
SP - 760
EP - 768
JO - American journal of epidemiology
JF - American journal of epidemiology
IS - 8
ER -